written by reader Discussion page for Arch Therapeutics (ARTH)

By Lynn Clark, Stock Gumshoe, November 6, 2017

This page is for discussion of Arch Therapeutics (ARTH).

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

816 Comments
Inline Feedbacks
View all comments
yelpik
Irregular
yelpik
February 12, 2019 2:10 pm

Anybody see presentation yesterday. Anything new?

👍 283
JohnM
Irregular
February 12, 2019 3:47 pm
Reply to  yelpik
👍 1992
Dsp
Irregular
Dsp
February 13, 2019 11:59 am
Reply to  JohnM

excellent and encouraging presentation. Thanks

👍 21
rlamore
Irregular
February 13, 2019 2:36 pm
Reply to  JohnM

Interesting, they seem to be primarily focusing on the commercialization of the tropical wound product for the rest of this year. TN did not mention anything about partnering in this area. That is a little concerning as to commercialize requires money. And although he mentioned the IDE in 2019, no mention of what quarter, which in my Project Manager mind means Dec of this year. But at least progress was made in 2018, let’s hope it continues.

👍 625
rlamore
Irregular
February 13, 2019 5:39 pm
Reply to  rlamore

Duh – topical not tropical, I guess I have Kauai on my mind.

👍 625
jerome50
Member
jerome50
February 14, 2019 10:48 pm
Reply to  rlamore

I am beginning to lose all confidence in Norchi, and it looks like the market feels the same way!!

👍 206
JohnM
Irregular
February 14, 2019 10:53 pm
Reply to  jerome50

What did you hear in the BIO presentation that made you begin to lose confidence in Norchi?

👍 1992
finventurer
Irregular
finventurer
February 23, 2019 6:47 am

$ARTH way-too-Long

Did anybody else hear sincere enthusiasm and confidence in Norchi’s voice? as far as i’m concerned, that was probably the best presentations Norchi’s given in long time. Almost sounded like he was relieved.

Might be the accelerated/narrow time frame too, but he could squeeze all the important points, including advancing in biosurgical program. i’m also quite impressed about the fact that they’ve (finally) implemented broader spectrum of AC5 topical indications in to their strategy – Dermal Sciences is a good start AND sounded very deeply thought of. Next stops are eye diseases and inflammations, right?

I’d say good work during 2018. Now get us the distributor/partner and off we go with uplisting too.

Add a Topic
4393
👍 352
Griffin
Irregular
Griffin
March 11, 2019 1:04 pm

$ARTH – Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

https://ir.archtherapeutics.com/press-releases/detail/523

ARTH long

Add a Topic
4393
👍 3679
Griffin
Irregular
Griffin
April 24, 2019 10:10 am